MA50155A - Acides aminés à chaîne ramifiée pour le traitement d'une lésion neuronale - Google Patents

Acides aminés à chaîne ramifiée pour le traitement d'une lésion neuronale

Info

Publication number
MA50155A
MA50155A MA050155A MA50155A MA50155A MA 50155 A MA50155 A MA 50155A MA 050155 A MA050155 A MA 050155A MA 50155 A MA50155 A MA 50155A MA 50155 A MA50155 A MA 50155A
Authority
MA
Morocco
Prior art keywords
branched
treatment
amino acids
chain amino
neuronal damage
Prior art date
Application number
MA050155A
Other languages
English (en)
Inventor
Raffi Afeyan
Sean Carroll
Rienzo Gianluca De
Matthew Russell
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of MA50155A publication Critical patent/MA50155A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0626—Isoleucine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0628—Leucine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0634—N-Acetyl-Cysteine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0654—Valine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds
    • A23V2250/306—Creatine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
MA050155A 2017-08-14 2018-08-14 Acides aminés à chaîne ramifiée pour le traitement d'une lésion neuronale MA50155A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545364P 2017-08-14 2017-08-14
US201862614198P 2018-01-05 2018-01-05
US201862697690P 2018-07-13 2018-07-13

Publications (1)

Publication Number Publication Date
MA50155A true MA50155A (fr) 2020-07-29

Family

ID=63449701

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050155A MA50155A (fr) 2017-08-14 2018-08-14 Acides aminés à chaîne ramifiée pour le traitement d'une lésion neuronale

Country Status (18)

Country Link
US (1) US20190046486A1 (fr)
EP (1) EP3684350A1 (fr)
JP (2) JP7370960B2 (fr)
KR (1) KR20200040276A (fr)
CN (1) CN111295186A (fr)
AU (1) AU2018318091A1 (fr)
BR (1) BR112020002244A2 (fr)
CA (1) CA3072092A1 (fr)
CL (1) CL2020000383A1 (fr)
CO (1) CO2020001627A2 (fr)
IL (1) IL272336A (fr)
JO (1) JOP20200035A1 (fr)
MA (1) MA50155A (fr)
MX (1) MX2020001766A (fr)
PE (1) PE20200748A1 (fr)
SG (1) SG11202001131TA (fr)
TW (1) TW201919602A (fr)
WO (1) WO2019036442A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11617731B2 (en) 2017-04-28 2023-04-04 Axcella Health, Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
JP7370960B2 (ja) * 2017-08-14 2023-10-30 アクセラ・ヘルス・インコーポレイテッド 神経細胞損傷の治療のためのアミノ酸組成物
SG11202001142VA (en) 2017-08-14 2020-03-30 Axcella Health Inc Amino acid compositions for the treatment of liver disease
AR115581A1 (es) 2018-06-20 2021-02-03 Axcella Health Inc Métodos de preparación de composiciones de aminoácidos
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
KR20250171484A (ko) * 2019-03-02 2025-12-08 인트라바이오 리미티드 질환을 치료하기 위한 류신, 아세틸 류신, 및 관련된 유사체
EP4192441A1 (fr) * 2020-08-06 2023-06-14 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Oléylcystéinamide ou dérivés de celui-ci et leurs utilisations en thérapie
US20220218640A1 (en) * 2021-01-14 2022-07-14 Rob Dickerman Amino acid delivery system
US11931127B1 (en) * 2021-04-08 2024-03-19 T-Mobile Usa, Inc. Monitoring users biological indicators using a 5G telecommunication network
JP2024529966A (ja) 2021-07-26 2024-08-14 アクセラ（アサインメント フォ ザ ベネフィット オブ クレディターズ），エルエルシー Ｃｏｖｉｄ－１９の急性期後後遺症の治療に使用するためのアミノ酸組成物及び方法
WO2024243004A2 (fr) * 2023-05-19 2024-11-28 The Children's Hospital Of Philadelphia Compositions et procédés de traitement d'une lésion cérébrale traumatique
US20250099382A1 (en) * 2023-09-26 2025-03-27 Robert Austin Chittenden Colloidal suspension of nutraceutical ingredients to treat traumatic brain injury
CN119235838A (zh) * 2024-11-04 2025-01-03 苏州市立医院 一种hmb在制备改善创伤性脑损伤药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438144A (en) * 1980-07-31 1984-03-20 Blackburn George L Amino acid preparation and therapy for treatment of stress and injury
US20050107338A1 (en) * 2003-11-17 2005-05-19 Seidman Michael D. Nutritional supplement enhancing mitochondrial function
EP1863472B1 (fr) * 2005-03-21 2013-02-20 Abbott Laboratories Composition d'acides amines pour ameliorer la tolerance au glucose
CN101693740B (zh) * 2009-10-16 2011-09-07 中国人民解放军第四军医大学 Homer1蛋白及其在治疗或预防脑损伤疾病中的应用
ES2893825T3 (es) * 2011-02-04 2022-02-10 Hough Ear Inst Métodos de tratamiento de lesiones cerebrales
WO2012125020A1 (fr) * 2011-03-14 2012-09-20 N.V. Nutricia Méthode de traitement d'un traumatisme neurologique
US20130090356A1 (en) * 2011-06-24 2013-04-11 Jon D. Kaiser Compositions and methods for treatment of neuropsychological deficits
CA2799127C (fr) * 2012-12-18 2021-05-18 Matthew Bennett Compositions et methodes pour traiter une lesion cerebrale traumatique
WO2014172341A1 (fr) 2013-04-16 2014-10-23 The Children's Hospital Of Philadelphia Compositions et méthodes pour le traitement des lésions cérébrales
CN106361738A (zh) * 2016-08-25 2017-02-01 南通大学 治疗、预防脑白质损伤的医药组合物及其医药用途
US20180133185A1 (en) * 2016-11-11 2018-05-17 The Children's Hospital Of Philadelphia Compositions and Methods for the Improvement of Memory
JOP20190147A1 (ar) * 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات
JOP20190146A1 (ar) * 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JP7370960B2 (ja) * 2017-08-14 2023-10-30 アクセラ・ヘルス・インコーポレイテッド 神経細胞損傷の治療のためのアミノ酸組成物

Also Published As

Publication number Publication date
CO2020001627A2 (es) 2020-06-09
BR112020002244A2 (pt) 2020-08-04
MX2020001766A (es) 2020-07-29
PE20200748A1 (es) 2020-07-24
WO2019036442A9 (fr) 2020-02-13
AU2018318091A1 (en) 2020-02-13
JP2023145496A (ja) 2023-10-11
JOP20200035A1 (ar) 2020-02-13
CN111295186A (zh) 2020-06-16
KR20200040276A (ko) 2020-04-17
US20190046486A1 (en) 2019-02-14
JP7370960B2 (ja) 2023-10-30
CL2020000383A1 (es) 2020-08-28
SG11202001131TA (en) 2020-03-30
TW201919602A (zh) 2019-06-01
EP3684350A1 (fr) 2020-07-29
CA3072092A1 (fr) 2019-02-21
IL272336A (en) 2020-03-31
AU2018318091A8 (en) 2020-03-12
WO2019036442A1 (fr) 2019-02-21
JP2020530843A (ja) 2020-10-29

Similar Documents

Publication Publication Date Title
MA49906A (fr) Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
EP3641829A4 (fr) Promédicament d'interféron pour le traitement du cancer
EP3455205A4 (fr) Peptidomimétiques pour le traitement d'une infection à norovirus
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
EP3642667C0 (fr) Lentille de contact d'orthokératologie pour le traitement de la myopie
EP3291842A4 (fr) Vaccin à base d'une variante de survivine pour le traitement du cancer
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
EP3645502A4 (fr) Procédé pour la séparation d'acides aminés et de diacides à longue chaîne
EP3558313A4 (fr) Substances pour le traitement d'affections liées à la stéatose hépatique
EP3405183A4 (fr) Dérivés d'adamatane pour le traitement d'une infection à filovirus
MA44864A (fr) Trithérapie pour le traitement d'une maladie intestinale inflammatoire
EP3440094A4 (fr) Inhibiteur de la localisation mitochondriale de tdp -43 pour le traitement d'une maladie neurodégénérative
EP3635130A4 (fr) Médicament de précision pour le traitement et la prévention du risque suicidaire
EP3737361A4 (fr) Inhibiteurs de la dihydrocéramide désaturase pour le traitement d'une maladie
EP3445352A4 (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
EP3463341A4 (fr) Immunomodulateurs à base d'aminocylindazole pour le traitement de maladies auto-immunes
EP3496662A4 (fr) Protéine dérivée de la soie pour le traitement d'une inflammation
EP3630102A4 (fr) Formulations pour le traitement d'un trouble de stress post-traumatique
EP3849573A4 (fr) Bactériothérapie contre proprionibacterium acnes pour le traitement de l'acné
EP3634426A4 (fr) Compositions pour le traitement d'une fibrose
EP3766497A4 (fr) Médicament pour le traitement de la toux
EP3285795A4 (fr) Oligopeptides amers administrés par voie entérique pour le traitement du diabète de type 2
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
EP3773221A4 (fr) Traitement pour l'hydrocéphalie